Atlas Trials

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

Clinical trial NCT06732505 · RECRUITING

Trial details

NCT number
NCT06732505
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neuroendocrine Neoplasm
Start date
2024-09-29
Primary completion
2025-12-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.